Latest Videos

SUI – AUA/SUFU Guidelines 2017 — Amendment 2023

SUI – AUA/SUFU Guidelines 2017 — Amendment 2023

Posted by | Dec 2024

Suzette E. Sutherland, MD, MS, URPS, discusses the AUA and SUFU guidelines for evaluating and treating stress urinary incontinence (SUI). In this five-minute talk, Dr. Sutherland reviews the five key components for evaluating a patient with SUI and discusses indications for advanced diagnostic tools such as cystoscopy and urodynamics.
Dr. Sutherland’s discussion continues with the Guideline’s treatment options, both non-surgical (pessaries, vaginal inserts, and pelvic floor muscle exercises), and surgical (bulking agents, midurethral slings). The recent amendment to the guidelines now allows clinicians to offer single-incision slings alongside retropubic and transobturator slings for patients, reflecting their comparable safety and effectiveness.

Read More
AUA Guidelines on Neurogenic Lower Urinary Tract Dysfunction

AUA Guidelines on Neurogenic Lower Urinary Tract Dysfunction

Posted by | Dec 2024

Stephen R. Kraus, MD, MBA, FACS, reviews the updated neurogenic lower urinary tract dysfunction (N-LUTD) guidelines, previously known as neurogenic bladder guidelines. In this 10-minute talk, he notes that the redefined terminology reflects a more comprehensive approach, addressing both bladder and outlet dysfunction.

Kraus explains patients are classified into low, moderate, or high-risk categories based on factors like neurological disease and bladder function. The guidelines use these categories when recommending treatment. Dr. Kraus gives examples, illustrating how the guidelines provide individualized patient treatment. Further, he emphasizes that the guidelines highlight the importance of ongoing monitoring to ensure treatment efficacy and prevent complications in high-risk patients.

Read More
Highlights from GU ASCO and ASCO 2024

Highlights from GU ASCO and ASCO 2024

Posted by | Dec 2024

A. Edward Yen, MD, reviews recent developments in prostate cancer treatment, summarizing key trials from recent oncology meetings. He begins this 29-minute presentation by outlining the evolving treatment landscape, from localized to metastatic castration-resistant prostate cancer. The focus narrows on select phase II and III trials involving novel therapeutics and treatment strategies.

Dr. Yen begins with the BRCAAway trial, which explores abiraterone, olaparib, and their combination in patients with metastatic CRPC harboring BRCA1/2 or ATM mutations. He then moves on to the Contact-02 study, which investigates cabozantinib and atezolizumab versus second-line hormonal therapy in metastatic CRPC patients. Continuing, he shares the results of the Embark study, which examined enzalutamide with or without androgen deprivation therapy in patients with non-metastatic CRPC.

Other notable studies include a negative evaluation of metformin for preventing progression in low-risk prostate cancer and an exploratory phase I trial of a novel human kallikrein-targeted radioligand therapy. Dr. Yen concludes with an overview of ARV-766, a PROTAC androgen receptor degrader showing strong PSA responses, highlighting its potential for future development in targeting resistant androgen receptor mutations in advanced CRPC.

Read More